The RAPS store will be under maintenance Saturday, 17 April between 5 AM and 12 PM EST. Store functionality may be unavailable at times during this window.
We apologize for any inconvenience caused during this time.

Regulatory Focus™ > News Articles > FDA Issues Interim Rule on Drug Production Discontinuance

FDA Issues Interim Rule on Drug Production Discontinuance

Posted 21 December 2011

The US Food and Drug Administration (FDA) issued an interim final rule last week that clarifies what a 'discontinuance' of production of a drug is and what 'sole manufacturer' means when it comes to a pharmaceutical company's duty to inform federal officials about a potential shortage. The new regulation defines a 'discontinuance' as either a permanent or temporary disruption in the supply of a product. Previously, companies had to inform FDA only when they permanently stopped making a particular medicine. The initiative would increase visibility about shortages between industry and the FDA, according to the trade group. It would also require acceptance by the Federal Trade Commission and Health and Human Services. (California Healthline)


© 2021 Regulatory Affairs Professionals Society.

Regulatory Focus newsletters

All the biggest regulatory news and happenings.